Sarah J. Glastras is a staff specialist in endocrinology at the Royal North Shore Hospital, Sydney, a researcher at the University of Sydney, and a consultant endocrinologist at the Northern Sydney Endocrine Centre. Her research interests lie in the area of metabolic dysregulation, obesity, and complications of diabetes. Her aim is to determine the molecular mechanisms that underlie the contribution of obesity and developmental programming towards end-organ damage with a particular focus on chronic kidney disease. Her research interests further comprise the contribution of the maternal in utero environment towards the future risk of offspring developing complex conditions, such as diabetes and chronic kidney disease. In addition, she is a clinical investigator in a large phase III clinical trial which is examining the effect of GLP-1 receptor stimulation using liraglutide on body weight and cardiac and neurological function in obese individuals with diabetes. She has also investigated the role of GLP-1 receptor stimulation in mitigating detrimental effects of obesity and insulin resistance in the kidneys. She serves as a member of the Australasian Diabetes in Pregnancy Society, Australian Diabetes Society, and Australian and New Zealand Obesity Society.